1. Home
  2. EXR vs ZTS Comparison

EXR vs ZTS Comparison

Compare EXR & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extra Space Storage Inc

EXR

Extra Space Storage Inc

HOLD

Current Price

$140.94

Market Cap

30.3B

Sector

Real Estate

ML Signal

HOLD

Logo Zoetis Inc.

ZTS

Zoetis Inc.

SELL

Current Price

$76.28

Market Cap

32.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EXR
ZTS
Founded
1977
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3B
32.5B
IPO Year
2004
2012

Fundamental Metrics

Financial Performance
Metric
EXR
ZTS
Price
$140.94
$76.28
Analyst Decision
Buy
Buy
Analyst Count
15
12
Target Price
$144.80
$154.18
AVG Volume (30 Days)
742.7K
5.2M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
4.61%
1.86%
EPS Growth
13.90
10.05
EPS
2.39
3.08
Revenue
$3,377,542,000.00
$9,467,000,000.00
Revenue This Year
N/A
$5.63
Revenue Next Year
$3.63
$4.77
P/E Ratio
$58.55
$24.73
Revenue Growth
3.70
2.28
52 Week Low
$125.71
$71.00
52 Week High
$158.88
$155.15

Technical Indicators

Market Signals
Indicator
EXR
ZTS
Relative Strength Index (RSI) 32.26 50.58
Support Level $139.88 $73.02
Resistance Level $146.69 $78.74
Average True Range (ATR) 2.21 2.21
MACD -0.75 0.13
Stochastic Oscillator 20.37 69.29

Price Performance

Historical Comparison
EXR
ZTS

About EXR Extra Space Storage Inc

Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.

About ZTS Zoetis Inc.

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Share on Social Networks: